Abstract:Abstract In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal growth factor receptor ( EGFR) T790M mutation ( n = 47) by modulating selective pressure on resistant clones. The primary endpoint is progression free-survival (PFS) rate at 12 months, and secondary endpoints include: feasibility of alternating therapy, overall response rate (ORR), overall survival (OS), and safety. The 12-month PFS rate is 38% (95% CI 27.5–55), not meeting the pre-specified primary endpoint. Serial circulating tumor DNA (ctDNA) analysis reveals decrease and clearance of the original activating EGFR and EGFR -T790M mutations which are prognostic of clinical outcomes. In 73% of participants, loss of T790M ctDNA is observed at progression and no participants have evidence of the EGFR C797S resistance mutation following the alternating regimen. These findings highlight the challenges of treatment strategies designed to modulate clonal evolution and the clinical importance of resistance mechanisms beyond suppression of selected genetic mutations in driving therapeutic escape to highly potent targeted therapies.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to delay the development of resistance to osimertinib in patients with advanced EGFR T790M - mutant - positive non - small - cell lung cancer (NSCLC) by alternating the use of osimertinib and gefitinib. Specifically, the researchers hope to influence tumor clonal evolution by adjusting the treatment selection pressure, thereby prolonging the patients' progression - free survival (PFS) and improving the treatment effect. ### Research Background - **EGFR Mutations**: Gene mutations in the epidermal growth factor receptor (EGFR) are key oncogenic drivers in non - small - cell lung cancer, and 85% of cases are caused by exon 19 deletion (del19) or exon 21 L858R point mutation. - **EGFR TKIs**: First - and second - generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib significantly improve the progression - free survival (PFS) of patients with advanced NSCLC with EGFR - mutant - positive. However, these drugs will eventually become ineffective due to the emergence of resistance. - **T790M Mutation**: Approximately 50 - 60% of patients will develop the T790M mutation after using first - or second - generation EGFR TKIs, which is one of the most common resistance mechanisms. - **Osimertinib**: A third - generation EGFR TKI that can simultaneously inhibit EGFR - sensitive mutations and T790M - resistant mutations, significantly improving the patients' PFS and overall survival (OS). ### Research Objectives - **Primary Endpoint**: Evaluate the 12 - month progression - free survival rate (PFS). - **Secondary Endpoints**: Evaluate the feasibility of alternating treatment, the overall response rate (ORR), overall survival (OS), and safety. ### Research Design - **Single - Arm Phase II Trial**: 47 patients with advanced NSCLC with EGFR T790M - mutant - positive were recruited. - **Treatment Regimen**: Patients first received induction treatment (osimertinib) and then entered the alternating treatment phase (alternating use of osimertinib and gefitinib). - **Follow - Up**: Genomic changes and resistance mechanisms were monitored by regularly collecting circulating tumor DNA (ctDNA) samples. ### Main Findings - **12 - Month PFS Rate**: 38% (95% CI 27.5 - 55), failing to reach the preset primary endpoint. - **ctDNA Analysis**: Most patients lost the T790M mutation at disease progression, and no EGFR C797S - resistant mutation was detected. - **Efficacy and Safety**: - Median PFS was 9.4 months (95% CI 7.2 - 13.0). - Median overall survival (OS) was 26 months (95% CI 19 - not estimable). - Objective response rate (ORR) was 45% (95% CI 31 - 59%). - The most common adverse events included diarrhea, fatigue, acne - like rash, cough, and headache. ### Conclusion Although alternating treatment failed to significantly improve the 12 - month PFS rate, ctDNA analysis shows that this treatment strategy may help delay the development of some resistance mechanisms, especially the loss of the T790M mutation. These findings emphasize the importance of considering tumor clonal evolution in treatment strategies and suggest that future research needs to further explore more effective methods of resistance prevention.

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

P2.09-33 A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation after Failure of Prior EGFR TKIs

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment

Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

Osimertinib As Neoadjuvant Therapy in Patients with EGFR-mutant Resectable Stage II-IIIB Lung Adenocarcinoma (NEOS): A Multicenter, Single-Arm, Open-Label Phase 2b Trial.

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy

Phase Ib/IIa Study Evaluating the Safety and Clinical Activity of Osimeritinib Combined with Anlotinib in EGFRm, Treatment-Naive Advanced NSCLC Patients (AUTOMAN).

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR -mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

Detect T790M in Cell Free Tumor DNA of Chinese Advanced Non-Small Cell Lung Cancer Adenocarcinoma Patients by Different Platforms and Evaluate Clinical Outcomes of T790M Positive Patients with Osimertinib Monotherapy